http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2721120-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_618b17106347ae6b808f7c508a7fd424 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4353 |
| filingDate | 2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c1be6abfedc4984d20281e41790fb54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee74d4b63e43b5c62af8dc1c6549229d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c2ecc42d390a46cdf4ca9c626a3a8d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6d234465b02984fd27b3c636976e5b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fde973a2d1d2a36b832178305619b9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51141fd93fc883f1070ddd7e4cd23546 |
| publicationDate | 2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2721120-C2 |
| titleOfInvention | Novel heterocyclic compounds as brd4 inhibitors |
| abstract | FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to a compound of formula (I) or a tautomeric form thereof, a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof, where in said formula ---- is a single bond or a double bond; X is selected from -O- or -N-; n equals 0–1; Ris C-C-alkyl; Rand Rare selected independently from hydrogen, halogen, hydroxy, C-C-halogenalkyl, independently substituted with up to three halogen atoms selected from fluorine, chlorine, bromine or iodine, C-C-alkoxy, C-C-haloalkoxy; Ris selected from C-C-alkyl, C-C-cycloalkyl, C-C-cycloalkylalkyl, C-C-aryl, C-C-heteroaryl or C-C-haloalkyl, where alkyl, cycloalkyl, cycloalkylalkyl, aryl and heteroaryl independently are unsubstituted or substituted by up to three substituents independently selected from halogen, C-C-alkyl and cyano, and where heteroaryl contains up to three heteroatoms selected from O, N or S atoms; Z is selected from hydrogen, -CHOR, -COOR, -CONRR, -NHCOORor -NHCOR, where Rand Rare independently selected from hydrogen, C-C-aryl or C-C-alkyl; where Rand Rare optionally substituted with one or more substitutes selected from hydroxy, oxo (=O) or C-C-alkyl. Invention also relates to a pharmaceutical composition based on said compounds.I.EFFECT: novel compounds and a pharmaceutical composition based thereon, which can be used in medicine for treating cancer.17 cl, 1 tbl, 46 ex |
| priorityDate | 2015-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 286.